Neurosurgical complications of direct thrombin inhibitors—catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran

Case report

Sarah T. Garber M.D., Walavan Sivakumar M.D. and Richard H. Schmidt M.D., Ph.D.
View More View Less
  • Department of Neurosurgery, University of Utah, Salt Lake City, Utah
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor. Large randomized clinical trials have shown higher doses of dabigatran (150 mg taken twice daily) to be superior to warfarin in terms of stroke and systemic embolism rates in patients with nonvalvular atrial fibrillation. As a result, in 2010 the US FDA approved the use of dabigatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Dabigatran is especially attractive in the outpatient setting because patients do not require routine monitoring with prothrombin times or international normalized ratios. To date, no effective reversal agent for dabigatran in the event of catastrophic hemorrhage has been identified. The authors report a case of an elderly patient, being treated with dabigatran for atrial fibrillation, who presented with a rapidly expanding intracranial hemorrhage after a ground-level fall. This case highlights an impending neurosurgical quandary of complications secondary to this new anticoagulation agent and suggests potential options for management.

Abbreviations used in this paper:GCS = Glasgow Coma Scale; SAH = subarachnoid hemorrhage.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address correspondence to: Richard H. Schmidt, M.D., Ph.D., Department of Neurosurgery, University of Utah, 175 North Medical Drive East, Salt Lake City, Utah 84132. email: neuropub@hsc.utah.edu.

Please include this information when citing this paper: published online March 6, 2012; DOI: 10.3171/2012.2.JNS112132.

  • 1

    Connolly SJ, , Ezekowitz MD, , Yusuf S, , Eikelboom J, , Oldgren J, & Parekh A, : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:11391151, 2009

    • Search Google Scholar
    • Export Citation
  • 2

    Eerenberg ES, , Kamphuisen PW, , Sijpkens MK, , Meijers JC, , Buller HR, & Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:15731579, 2011

    • Search Google Scholar
    • Export Citation
  • 3

    Eikelboom JW, , Wallentin L, , Connolly SJ, , Ezekowitz M, , Healey JS, & Oldgren J, : Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:23632372, 2011

    • Search Google Scholar
    • Export Citation
  • 4

    Ganetsky M, , Babu KM, , Salhanick SD, , Brown RS, & Boyer EW: Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 7:281287, 2011

    • Search Google Scholar
    • Export Citation
  • 5

    Hart RG, , Benavente O, , McBride R, & Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492501, 1999

    • Search Google Scholar
    • Export Citation
  • 6

    Hart RG, , Pearce LA, & Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857867, 2007

    • Search Google Scholar
    • Export Citation
  • 7

    Medi C, , Hankey GJ, & Freedman SB: Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 41:27052713, 2010

  • 8

    Stangier J, , Stähle H, , Rathgen K, & Fuhr R: Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:4759, 2008

    • Search Google Scholar
    • Export Citation
  • 9

    Teasdale G, & Jennett B: Assessment of coma and impaired consciousness: a practical scale. Lancet 2:8184, 1974

  • 10

    Zhou W, , Schwarting S, , Illanes S, , Liesz A, , Middelhoff M, & Zorn M, : Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42:35943599, 2011

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 914 327 32
Full Text Views 340 10 3
PDF Downloads 174 7 0
EPUB Downloads 0 0 0